Effect of Ziv-Aflibercept in the Bevacizumab Pre-Treated Subgroup of Patients in VELOUR

Article

Paulo Marcelo Hoff, MD, PhD, FACP, discusses a trial that looked at the consistency of effect of ziv-aflibercept in the bevacizumab pre-treated subgroup of patients in the VELOUR trial stratified by first-line progression ≥ 9 months versus < 9 months.

Paulo Marcelo Hoff, MD, PhD, FACP, University of S&atilde;o Paulo, Brazil, discusses a trial presented at the 2014 ASCO Annual Meeting that looked at the consistency of effect of ziv-aflibercept in the bevacizumab pre-treated subgroup of patients in the VELOUR trial stratified by first-line progression &ge; 9 months versus < 9 months.

<<<

Back to the ASCO 2014 conference page

Related Videos
Related Content